title: Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis.
abstract: To evaluate the prognostic value of the absolute lymphocyte count/absolute monocyte count ratio (ALC/AMC ratio) at diagnosis in diffuse large B-cell lymphoma (DLBCL), we performed a meta-analysis of published studies that provided survival information with reference to the ALC/AMC ratio at diagnosis. Nine studies covering a total of 4198 subjects were included in this analysis. The summary hazard ratios of low ALC/AMC ratio for overall survival were 2.00 (p = 0.000) in the population that received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and 1.12 (p = 0.479) in the population that received CHOP. The corresponding ratios for event-free survival and progression-free survival were 1.93 (p = 0.000) and 2.31 (p = 0.000) in the population that received R-CHOP. These results may justify risk-adapted therapeutic strategies for patients with DLBCL treated with R-CHOP to account for the ALC/AMC ratio at diagnosis.
authors: a Division of Radiation Oncology and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , P. R. China.
authors: Baochai
authors: B
authors: Lin
authors: b Division of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , P. R. China.
authors: Cuie
authors: C
authors: Chen
authors: b Division of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , P. R. China.
authors: Yan
authors: Y
authors: Qian
authors: c Division of Pediatric Hematology-Oncology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , P. R. China.
authors: Jianhua
authors: J
authors: Feng
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007958:Leukocyte Count; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D009000:Monocytes / Q000473:pathology*; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D016016:Proportional Hazards Models; D000069283:Rituximab / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Diffuse large B-cell lymphoma; lymphocyte; meta-analysis; monocyte; prognosis